PH12022552172A1 - High concentration anti-aã protofibril antibody formulations and methods of use thereof - Google Patents
High concentration anti-aã protofibril antibody formulations and methods of use thereofInfo
- Publication number
- PH12022552172A1 PH12022552172A1 PH1/2022/552172A PH12022552172A PH12022552172A1 PH 12022552172 A1 PH12022552172 A1 PH 12022552172A1 PH 12022552172 A PH12022552172 A PH 12022552172A PH 12022552172 A1 PH12022552172 A1 PH 12022552172A1
- Authority
- PH
- Philippines
- Prior art keywords
- methods
- high concentration
- protofibril antibody
- antibody formulations
- concentration anti
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062992746P | 2020-03-20 | 2020-03-20 | |
| US202063027263P | 2020-05-19 | 2020-05-19 | |
| PCT/IB2021/000155 WO2021186245A1 (en) | 2020-03-20 | 2021-03-19 | HIGH CONCENTRATION ANTI-Aß PROTOFIBRIL ANTIBODY FORMULATIONS AND METHODS OF USE THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12022552172A1 true PH12022552172A1 (en) | 2023-12-11 |
Family
ID=75746958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2022/552172A PH12022552172A1 (en) | 2020-03-20 | 2021-03-19 | High concentration anti-aã protofibril antibody formulations and methods of use thereof |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20230183328A1 (https=) |
| EP (2) | EP4121007B1 (https=) |
| JP (2) | JP7689141B2 (https=) |
| KR (1) | KR20220156534A (https=) |
| CN (1) | CN115315251A (https=) |
| AU (1) | AU2021238951A1 (https=) |
| BR (1) | BR112022018766A2 (https=) |
| CA (1) | CA3174778A1 (https=) |
| CL (2) | CL2022002517A1 (https=) |
| CO (1) | CO2022012916A2 (https=) |
| DK (1) | DK4121007T3 (https=) |
| ES (1) | ES3041762T3 (https=) |
| FI (1) | FI4121007T3 (https=) |
| HR (1) | HRP20251087T1 (https=) |
| HU (1) | HUE072937T2 (https=) |
| IL (2) | IL295383B1 (https=) |
| LT (1) | LT4121007T (https=) |
| MA (1) | MA59082B1 (https=) |
| MD (1) | MD4121007T2 (https=) |
| MX (1) | MX2022011101A (https=) |
| PH (1) | PH12022552172A1 (https=) |
| PL (1) | PL4121007T3 (https=) |
| PT (1) | PT4121007T (https=) |
| RS (1) | RS67249B1 (https=) |
| SI (1) | SI4121007T1 (https=) |
| SM (1) | SMT202500350T1 (https=) |
| WO (1) | WO2021186245A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230039734A (ko) | 2020-07-23 | 2023-03-21 | 오타이르 프로테나 리미티드 | 항-Aβ 항체 |
| AU2022307687A1 (en) | 2021-07-09 | 2024-01-04 | Eisai R&D Management Co., Ltd. | Biomarkers for alzheimer's disease treatment |
| AU2022439338A1 (en) | 2022-02-02 | 2024-08-15 | Eisai R&D Management Co., Ltd. | Methods of treatment using p-tau181 level |
| JP2025539394A (ja) | 2022-11-28 | 2025-12-05 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | タウｐｅｔレベルを使用する治療の方法 |
| KR20260022396A (ko) | 2023-06-09 | 2026-02-19 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 항-Aβ 프로토피브릴 항체를 사용한 치료 방법 |
| WO2026015877A1 (en) | 2024-07-12 | 2026-01-15 | Eisai R&D Management Co., Ltd. | Fluid biomarker |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20091174A1 (es) * | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| CN118370815A (zh) | 2017-08-22 | 2024-07-23 | 渤健马萨诸塞州股份有限公司 | 含有抗β淀粉样蛋白抗体的药物组合物 |
| US20210324056A1 (en) | 2018-07-24 | 2021-10-21 | Eisai R&D Management Co., Ltd. | Methods of treatment and prevention of alzheimer's disease |
-
2021
- 2021-03-19 RS RS20250922A patent/RS67249B1/sr unknown
- 2021-03-19 EP EP21722538.2A patent/EP4121007B1/en active Active
- 2021-03-19 BR BR112022018766A patent/BR112022018766A2/pt unknown
- 2021-03-19 KR KR1020227030919A patent/KR20220156534A/ko active Pending
- 2021-03-19 PL PL21722538.2T patent/PL4121007T3/pl unknown
- 2021-03-19 MX MX2022011101A patent/MX2022011101A/es unknown
- 2021-03-19 IL IL295383A patent/IL295383B1/en unknown
- 2021-03-19 FI FIEP21722538.2T patent/FI4121007T3/fi active
- 2021-03-19 WO PCT/IB2021/000155 patent/WO2021186245A1/en not_active Ceased
- 2021-03-19 CN CN202180019180.6A patent/CN115315251A/zh active Pending
- 2021-03-19 PH PH1/2022/552172A patent/PH12022552172A1/en unknown
- 2021-03-19 AU AU2021238951A patent/AU2021238951A1/en active Pending
- 2021-03-19 US US17/906,660 patent/US20230183328A1/en active Pending
- 2021-03-19 MD MDE20230104T patent/MD4121007T2/ro unknown
- 2021-03-19 SI SI202130347T patent/SI4121007T1/sl unknown
- 2021-03-19 PT PT217225382T patent/PT4121007T/pt unknown
- 2021-03-19 IL IL326613A patent/IL326613A/en unknown
- 2021-03-19 DK DK21722538.2T patent/DK4121007T3/da active
- 2021-03-19 EP EP23179487.6A patent/EP4252777A3/en active Pending
- 2021-03-19 SM SM20250350T patent/SMT202500350T1/it unknown
- 2021-03-19 JP JP2022556091A patent/JP7689141B2/ja active Active
- 2021-03-19 HU HUE21722538A patent/HUE072937T2/hu unknown
- 2021-03-19 LT LTEPPCT/IB2021/000155T patent/LT4121007T/lt unknown
- 2021-03-19 MA MA59082A patent/MA59082B1/fr unknown
- 2021-03-19 HR HRP20251087TT patent/HRP20251087T1/hr unknown
- 2021-03-19 CA CA3174778A patent/CA3174778A1/en active Pending
- 2021-03-19 ES ES21722538T patent/ES3041762T3/es active Active
-
2022
- 2022-09-12 CO CONC2022/0012916A patent/CO2022012916A2/es unknown
- 2022-09-14 CL CL2022002517A patent/CL2022002517A1/es unknown
-
2024
- 2024-11-08 CL CL2024003428A patent/CL2024003428A1/es unknown
-
2025
- 2025-04-10 JP JP2025064827A patent/JP2025111516A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022552172A1 (en) | High concentration anti-aã protofibril antibody formulations and methods of use thereof | |
| CY1123667T1 (el) | Παρασκευασμα ανοσοσφαιρινης και μεθοδος παρασκευης αυτου | |
| CL2019002478A1 (es) | Formulación de anticuerpo monoclonal anti-vrs. | |
| MY210499A (en) | Anti-sars-cov-2 infection protein and vaccine | |
| JOP20220179A1 (ar) | N4-هيدروكسي سيتيدين ومشتقات واستخدامات مضادة للفيروسات مرتبطة بها | |
| EP4233892A3 (en) | Stable anti-ifnar1 formulation | |
| MX2023009971A (es) | Composicion farmaceutica que contiene anticuerpo anti-tslp. | |
| PE20091852A1 (es) | Formulacion farmaceutica que comprende un anticuerpo de ox40l | |
| AR067011A1 (es) | Formulaciones de anticuerpos | |
| SA521430342B1 (ar) | تركيبة سائلة تشتمل على جسم مضاد لمستقبل ألفا إنترليوكين -4 البشري | |
| MY199968A (en) | Formulations of an lsd1 inhibitor | |
| BR112022016456A2 (pt) | Formulações de anticorpos anti-tslp humanos e métodos de uso dos mesmos | |
| MX2023004032A (es) | Terapias inmuno-oncologicas con conjugados de il-2. | |
| CY1112082T1 (el) | Υγρη φαρμακοτεχνικη μορφη fsh | |
| PH12021551916A1 (en) | Therapeutic antibody formulation. | |
| PH12023550032A1 (en) | Tubulysins and protein-tubulysin conjugates | |
| WO2022099187A3 (en) | Sars-cov-2 antigen-binding proteins and uses thereof | |
| MX2022012001A (es) | Tratamiento preventivo de la migra?a. | |
| WO2023009759A3 (en) | Antibody-drug conjugates and methods of use thereof | |
| BR112022022620A2 (pt) | Formulações de anticorpos anti-il-33 | |
| MX2022010454A (es) | Uso de analogos de ciclosporina para el tratamiento contra el cancer. | |
| MX2025002407A (es) | Inhibidores de egfr y sus usos | |
| AR045074A1 (es) | Uso de cd164 soluble en desordenes inflamatorios y autoinmunes | |
| JOP20210315B1 (ar) | إستر لـ -حمض أسيتيك أيزو بروبيل لعلاج السعال المزمن | |
| MX2023000601A (es) | Composicion farmaceutica acuosa que comprende un antagonista del receptor p2y12. |